JHL Biotech, Inc. was established in 2012 with a vision of making world-class biopharmaceuticals affordable and accessible to all patients globally. JHL has its headquarters, research, and manufacturing facilities in Taiwan to support all pre-clinical and early clinical biologic development and a commercial manufacturing facility in Wuhan, China to deliver manufacturing solutions to its worldwide partners.
In June 2014, Milestone Capital was the lead investor in the Series B equity financing for JHL Biotech.